Please login to the form below

Not currently logged in
Email:
Password:

Aveo

This page shows the latest Aveo news and features for those working in and with pharma, biotech and healthcare.

NICE backs EUSA's RCC treatment Fotivda

NICE backs EUSA's RCC treatment Fotivda

cases. EUSA licenced Fotivda from Aveo Pharmaceuticals back in 2015, but although it has European approval in advanced renal cell carcinoma it failed to gain approval from the US Food and ... However, Aveo Oncology is looking to re-file Fotivda in the

Latest news

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory antibody for oesophageal cancer.

  • Deal Watch December 2015 Deal Watch December 2015

    405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Another early stage deal [opportunities do not seem to hang around long!] was that between Novartis and Aveo where Novartis paid an upfront fee of $15m to secure rights to AV ... Collaboration extension. 330. Aveo. Novartis. AV 380 antibody for

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Pharma deals during February 2014 Pharma deals during February 2014

    In another termination of an oncology deal, Astellas exercised its right to terminate its collaboration with Aveo Oncology to develop the tyrosine kinase inhibitor, tivozanib, for “ strategic reasons”.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance

    He joins the biopharma from Tang Capital Management. AVEO Oncology has appointed Dr Nikhil Mehta as senior vice president or regulatory and quality assurance, a role that will see him oversee ... I anticipate Dr Mehta’s integration into the AVEO team

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role. ... Johnston's switch comes after more than six years at AVEO having joined the company from his role as senior VP of finance

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics